Skip to main content
. Author manuscript; available in PMC: 2023 May 10.
Published in final edited form as: J Pharm Biomed Anal. 2022 Feb 28;213:114696. doi: 10.1016/j.jpba.2022.114696

Table 7.

Stability of cefazolin under different storage conditions.

Human samples
Rat samples
mean accuracy [%] CV [%] (n=3) mean accuracy [%] CV [%] (n=3)

adipose tissue homogenate stability
• bench-top [20°C, 6 h]
 LQC 98.1 9.6 100.9 1.8
 ULOQ 96.6 1.0 97.8 3.0
• freeze-thaw [−80°C, 3 cycles]
 LQC 102.0 0.4 - -
 ULOQ 90.0 3.4 - -
• long-term [−80°C, 8 weeks]
 LQC 92.3 5.5 - -
 ULOQ 97.7 0.9 - -
in-filtrate stability
• short-term [10°C, 24 h]
 LQC 98.8 2.6 102.9 5.2
 ULOQ 99.3 3.5 97.6 1.4
• long-term [−20°C, 12 days]
 LQC - - 112.4 2.1
 ULOQ - - 106.0 2.2
aqueous solutions stability
• stock solution [−20°C, 11 weeks]
 LQC - - 100.3 4.5
 ULOQ - - 100.4 4.5
• working solutions [−20°C, 4 weeks]
 LQC - - 102.7 2.0
 ULOQ - - 95.9 4.0

LQC = 0.1 μg/mL, ULOQ = 50 μg/mL of cefazolin in adipose tissue homogenate.